Viridian Therapeutics Inc (VRDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -222,246 | -187,647 | -86,912 | -269,949 | -190,224 |
| Depreciation Amortization | -4,665 | -3,642 | -2,100 | -15,115 | -12,031 |
| Accounts payable and accrued liabilities | 7,942 | 6,396 | 1,765 | -73 | 3,850 |
| Other Working Capital | -58,318 | 2,010 | -13,855 | 9,598 | 9,138 |
| Other Operating Activity | 24,650 | 14,857 | 8,449 | 43,220 | 30,280 |
| Operating Cash Flow | $-252,637 | $-168,026 | $-92,653 | $-232,319 | $-158,987 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 302,112 | 175,908 | 100,148 | -228,140 | -165,339 |
| PPE Investments | -255 | -128 | -86 | -511 | -397 |
| Investing Cash Flow | $301,857 | $175,780 | $100,062 | $-228,651 | $-165,736 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 21,249 | 10,183 | 9,419 | 459,678 | 422,844 |
| Common Stock Repurchased | -416 | -207 | N/A | N/A | -24,132 |
| Other Financing Activity | 0 | 0 | -207 | -1,941 | 23,501 |
| Financing Cash Flow | $20,833 | $9,976 | $9,212 | $457,737 | $422,213 |
| Beginning Cash Position | 99,594 | 99,594 | 99,594 | 102,827 | 102,827 |
| End Cash Position | 169,647 | 117,324 | 116,215 | 99,594 | 200,317 |
| Net Cash Flow | $70,053 | $17,730 | $16,621 | $-3,233 | $97,490 |
| Free Cash Flow | |||||
| Operating Cash Flow | -252,637 | -168,026 | -92,653 | -232,319 | -158,987 |
| Capital Expenditure | -255 | -128 | -86 | -511 | -397 |
| Free Cash Flow | -252,892 | -168,154 | -92,739 | -232,830 | -159,384 |